IDRS Labs and DAE Work Together to Develop Aktocyte Tablets for Cancer

With the help of IDRS Labs and the Department of Atomic Energy (DAE), professionals are advancing cancer care through the use of Aktocyte tablets, a significant advancement in the treatment of pelvic cancer, according to DAE

In a historic partnership, researchers from Bengaluru-based IDRS Labs and the Department of Atomic Energy (DAE) pooled their knowledge to create Aktocyte pills, which are intended to cure pelvic cancer. The DAE said in a statement that the tablets, which are intended to be an adjuvant to cancer radiation therapy, regenerative nutraceutical, immunomodulator, and antioxidant, represent a major breakthrough in cancer care.

Collaboration for Progress IDRS Labs has partnered with experts from the Bhabha Atomic Research Centre in Mumbai, the Advanced Centre for Training Research and Education in Cancer in Navi Mumbai, and Tata Memorial Hospital in Mumbai on this ground-breaking project. In order to solve the difficulties presented by treating pelvic cancer, the collaboration combines the expertise and resources of top institutions, with a particular emphasis on reducing the negative effects of radiation.

Goal: Reducing Radiation Adverse Effects

This cooperative effort’s main goal is to reduce radiation therapy’s adverse effects, which are an essential part of cancer treatment. Although radiotherapy is a popular therapeutic method, patients’ quality of life is frequently negatively impacted by its severe side effects. The goal of the research is to increase the effectiveness of cancer radiation therapy while lowering its side effects. To this end, Aktocyte pills have been developed as an adjuvant.

Aktocyte Tablets’ Novel Features

Because of their multipurpose architecture, Aktocyte tablets are a flexible adjunct to cancer therapy. The pills function as a regenerative nutraceutical, assisting the body’s inherent healing mechanisms. They also have the ability to modulate immunity, strengthening the body’s defenses against cancerous cells. Furthermore aiding in preventing harm to healthy cells during radiation therapy are the antioxidant qualities of Aktocyte.

Read also:-Defense Minister Signals Himalayan Mountaineering Team’s “Mission Antarctica”

FSSAI approval

The approval of Aktocyte by the Food Safety and Standards Authority of India (FSSAI) adds to the significance of this treatment for cancer patients. With this regulatory certification, users can feel confident using the pills as part of cancer treatment procedures since they know they fulfill all safety and quality standards.

Changing the Treatment of Pelvic Cancer

With regulatory approval and multifunctional features, Aktocyte tablets present a promising treatment option for pelvic cancer. By reducing treatment-related side effects, this novel method prioritizes patient care while simultaneously increasing the efficacy of radiation therapy.

Which academic institutions are actively taking part in this joint venture?

The partnership comprises experts from Bengaluru-based IDRS Labs as well as those from the Bhabha Atomic Research Centre, Tata Memorial Hospital in Mumbai, and the Advanced Centre for Training Research and Education in Cancer in Navi Mumbai.

What part do Aktocyte pills play in the management of cancer?

In order to improve the treatment of cancer, Aktocyte tablets work as an adjuvant to cancer radiation, regenerative nutraceutical, immunomodulator, and antioxidant.

Why is it that reducing side effects during cancer radiation is so important?

In order to improve patients’ quality of life both during and after treatment, as well as to provide a more favorable overall experience, it is imperative to minimize side effects in cancer radiation.